Results 11 to 20 of about 10,401 (200)

Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence [PDF]

Frontiers in Immunology
Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES.
Elvira Mora, María Laura Fox, María Laura Fox, Angelina Lemes, Beatriz Velasco, Jesús María Hernández-Rivas, Jesús María Hernández-Rivas   +6 more
doaj   +2 more sources

Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission [PDF]

The Korean Journal of Internal Medicine
Background/Aims This study investigated the clinical efficacy of low-dose mepolizumab (100 mg) in controlling severe eosinophilic asthma, aiming to induce eosinophilic granulomatosis with polyangiitis (EGPA) remission and reduce systemic steroid usage ...
Mi-Ae Kim, Ji-Hyun Lee, Eun-Kyung Kim, Jung-Hyun Kim, Jisoo Park, Se Hee Lee, Tae-Bum Kim   +6 more
doaj   +2 more sources

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: Findings From the European CRS Outcome Registry (CHRINOSOR). [PDF]

Clin Transl Allergy
ABSTRACT Background The SYNAPSE phase 3 study demonstrated that mepolizumab significantly improves nasal polyp score (NPS), quality of life and symptom severity in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Objective We aimed to evaluate mepolizumab effectiveness in a real‐world cohort from 12 tertiary centers in 6 European ...
Alobid I, Seys SF, de Kinderen J, Hox V, Cavaliere C, Andrianakis A, Schneider S, Wagenmann M, Bruch M, Izquierdo-Domínguez A, Gonzalez-Compta X, Muñoz LP, Van Gerven L, Hellings PW, Mortuaire G, Burian M, Golet-Fors M, Moyaert M, Tomazic PV, Bettio G, de Vincentiis M, Diamant Z, Eckl-Dorna J, Mariën G, Masieri S, Morgenstern C, Scheckenbach K, Tu A, Rodriguez van Strahlen C, Bachert C, CHRINOSOR consortium.   +30 more
europepmc   +2 more sources

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

Frontiers in Pharmacology, 2023
Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li, Chongshu Wang, Aiping Deng, Cuilian Guo   +3 more
doaj   +1 more source

Mepolizumab [PDF]

Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Cada, Dennis J, Bindler, Ross J, Baker, Danial E   +2 more
openaire   +3 more sources

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Respirology Case Reports, 2023
Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue   +9 more
doaj   +1 more source

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Allergy, Asthma & Clinical Immunology, 2023
Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto, Chiyako Oshikata, Ryo Nakadegawa, Yuto Motobayashi, Reeko Osada, Saki Manabe, Takeshi Kaneko, Naomi Tsurikisawa   +7 more
doaj   +1 more source

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma

Frontiers in Pharmacology, 2023
Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo, Christian Domingo, Ana Sogo, Ana Sogo, Enrique Casado, Eva Martínez-Moragón, Marina Blanco-Aparicio, Teresa Carrillo, Teresa Carrillo, David Bañas-Conejero, María-Guadalupe Sánchez-Herrero   +10 more
doaj   +1 more source

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype

Biomedicines, 2022
Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez, Paloma Poza-Guedes, Elena Mederos-Luis, Inmaculada Sánchez-Machín   +3 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source